Amlodipine Therapy for Hypertensive Patients with Chest Pain

Safety Profile in Patients with Chest Pain

Amlodipine, a dihydropyridine calcium channel blocker, has been documented as safe in patients with coronary heart disease and angina, with studies showing no increased risk of adverse cardiac events, according to the European Heart Journal 1, 2
The American Heart Association recommends amlodipine as a safe option for patients with severe heart failure, as it does not worsen heart failure symptoms, as shown in the PRAISE trial (Prospective Randomized Amlodipine Survival Evaluation) 3, 4
The ALLHAT trial demonstrated that amlodipine was as effective as other antihypertensive medications in hypertensive coronary patients with no significant differences in coronary and cardiovascular events, as reported by the European Heart Journal 1

The European Society of Cardiology recommends amlodipine for use in patients with heart failure when hypertension persists despite standard heart failure therapy 5
In acute coronary events with hypertension, the American College of Cardiology suggests that amlodipine is a suitable option for ongoing management, after initial treatment with nitroglycerine 6
The American Heart Association notes that amlodipine should be used with caution in patients with severe aortic stenosis or hypertrophic cardiomyopathy, due to its vasodilatory effects, and close monitoring is recommended when initiating therapy in heart failure patients 3

The American College of Cardiology recommends calcium channel blockers including amlodipine for ischemic symptoms when beta-blockers are not successful, contraindicated, or cause unacceptable side effects 7
In the VALUE trial involving over 15,000 high-risk hypertensive patients followed for 5 years, amlodipine showed no significant difference in cardiac events and death compared to valsartan, with a significant reduction in myocardial infarction 8

A 3-year randomized trial showed amlodipine decreased renal function decline in hypertensive patients with non-diabetic nephropathies 9

The American College of Cardiology recommends amlodipine as first-line therapy in elderly patients with isolated systolic hypertension, as it has demonstrated superior stroke prevention compared to other antihypertensive classes 10
Amlodipine is preferred when hypertension coexists with angina, as beta-blockers and dihydropyridine calcium channel blockers are recommended for this condition 11
The European Society of Cardiology notes that amlodipine demonstrated similar cardiovascular outcomes to other major antihypertensive classes in the ALLHAT trial, with no significant differences in coronary and cardiovascular events 12

The American Heart Association recommends amlodipine for symptom relief in chronic stable angina when beta-blockers are contraindicated or cause unacceptable side effects 13
Amlodipine provides additional symptom control when combined with beta-blockers in patients with chronic stable angina 13

The European Society of Cardiology states that amlodipine has neutral metabolic effects and does not impair insulin sensitivity, making it a suitable option for patients with diabetes 11

The European Society of Cardiology recommends that dihydropyridine calcium antagonists like amlodipine can be added to standard heart failure therapy if hypertension persists, particularly if concomitant angina is present 14, 12
Non-dihydropyridine calcium channel blockers should be avoided in heart failure with reduced ejection fraction as they can worsen left ventricular dysfunction 11

The European Society of Cardiology notes that amlodipine produced similar cardiac events and death compared to valsartan in the VALUE trial, with a significant reduction in myocardial infarction 15
The INVEST study demonstrated similar cardiovascular outcomes between amlodipine-based and beta-blocker-based regimens in hypertensive coronary patients 14, 12